Regeneron expects $83 million Q3 2025 charge, cutting EPS by about $0.68
Regeneron said its preliminary third quarter 2025 GAAP and non-GAAP results will include an acquired in-process research and development charge of about $83 million before taxes. The charge mainly relates to the previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals under a 2025 license agreement, and is expected to reduce net income per diluted share by about $0.68. The figures are unaudited and not yet final, so actual results could differ.
Key points
- Expected acquired IPR&D charge of about $83 million pre-tax for the quarter ended September 30, 2025
- Charge mainly relates to the $80 million up-front payment to Hansoh Pharmaceuticals Group under the 2025 license agreement
- Expected impact of about $0.68 per diluted share on both GAAP and non-GAAP net income
- Results are preliminary and subject to financial statement closing procedures
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:21 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.